Leap Therapeutics, Inc.
LPTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Gross Profit | $0 | -$0 | $0 | $0 |
| % Margin | – | – | – | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -2,702.7% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -2,705.8% |
| EPS Diluted | -1.81 | -3.98 | -4.82 | -4.73 |
| % Growth | 54.5% | 17.4% | -1.9% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |